Free Trial
→ $5,000 DOGE check? (From Altimetry) (Ad)

Acelyrin Q4 2023 Earnings Report

Acelyrin logo
$2.60 +0.43 (+19.82%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Acelyrin EPS Results

Actual EPS
-$0.75
Consensus EPS
-$1.00
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A

Acelyrin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Acelyrin Announcement Details

Quarter
Q4 2023
Date
3/28/2024
Time
N/A

Conference Call Resources

Powered by Quartr

Acelyrin Earnings Headlines

Acelyrin Stock Jumps on Concentra Acquisition Interest
February 21 at 4:23 PM | marketwatch.com
Acelyrin Stock Jumps on Concentra Acquisition Interest
February 21 at 4:23 PM | marketwatch.com
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
February 22, 2025 | Altimetry (Ad)
Acelyrin confirms unsolicited indication of interest from Concentra Biosciences
February 21 at 1:46 AM | markets.businessinsider.com
Acelyrin jumps 11% on acquisition offer from Concentra Biosciences
February 21 at 1:46 AM | msn.com
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
February 20 at 9:00 PM | globenewswire.com
See More Acelyrin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Acelyrin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acelyrin and other key companies, straight to your email.

About Acelyrin

Acelyrin (NASDAQ:SLRN), a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

View Acelyrin Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles